Latest Biotech News

Merck reported that its once-daily two-drug islatravir combination was non-inferior to a three-drug regimen in a Phase 3 study, marking another clinical success in the company’s effort to expand...

Profluent closed a $106 million financing led by Altimeter Capital and Bezos Expeditions to expand its large‑scale AI models for protein design and commercialize across therapeutics, agriculture...

Iambic closed an oversubscribed $100 million financing to advance its AI platforms — Enchant for clinical endpoint prediction and NeuralPLexer for protein-ligand structure forecasts — and...

Nvidia announced a three‑year collaboration with Sheba Medical Center’s ARC Innovation and Mount Sinai to develop a Genomic Foundation Model (gFM) that links genetic variation — especially...

Roche struck a licensing and commercialization agreement with Freenome worth potentially more than $200 million — including a $75 million equity stake — to commercialize Freenome’s blood‑based...

The FDA approved ziftomenib (Komzifti), an oral selective menin inhibitor, for relapsed/refractory NPM1‑mutant acute myeloid leukemia (AML), delivering clearance more than two weeks ahead of the...

Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash, buying a pipeline built on Halda’s Regulated Induced Proximity Targeting Chimera (RIPTAC) platform. The deal...

The FDA approved Arrowhead Pharmaceuticals’ RNA interference therapy plozasiran (Redemplo) for familial chylomicronemia syndrome, marking the company’s transition to commercial-stage operations....

Roche reported that its oral selective estrogen receptor degrader giredestrant met the primary endpoint in a Phase III adjuvant study, extending invasive disease‑free survival versus standard...

Zymeworks and partners Jazz Pharmaceuticals and BeOne reported positive top‑line results from the HERIZON‑GEA‑01 Phase III trial: zanidatamab (Ziihera) plus chemotherapy improved progression‑free...

Merck agreed to acquire Cidara Therapeutics for $9.2 billion to secure CD388, a long‑acting, strain‑agnostic influenza antiviral advancing in Phase III. Merck framed the deal as a strategic...

The U.S. FDA approved ziftomenib (Komzifti), the selective oral menin inhibitor developed by Kura Oncology and Kyowa Kirin, for relapsed or refractory NPM1‑mutant acute myeloid leukemia, granting...

GSK agreed to an upfront payment for access to LTZ Therapeutics’ myeloid cell engager (MCE) platform, joining other Big Pharma entrants pursuing myeloid‑directed immune‑engager modalities. The...

Roche agreed to a multiyear collaboration and equity investment with Freenome to commercialize Freenome’s blood‑based cancer screening tests outside the U.S., a deal potentially worth more than...

U.S. health manufacturers and experts raised alarms after reporting that the administration—led by Health Secretary Robert F. Kennedy Jr.—is weighing major vaccine policy changes, including...

Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash to add Halda’s RIPTAC-derived precision oncology portfolio to J&J’s pipeline. The deal centers on HLD-0915, a...

The FDA approved Arrowhead Pharmaceuticals’ RNAi therapeutic Redemplo (plozasiran) for familial chylomicronemia syndrome (FCS), marking Arrowhead’s entry into the commercial stage and the second...

Roche reported positive Phase III results showing its oral selective estrogen receptor degrader (SERD) extended invasive disease-free survival versus standard hormone therapy in patients with...

Zymeworks, together with development partner Jazz Pharmaceuticals, announced positive topline results from the Phase III HERIZON-GEA-01 trial of the HER2-directed bispecific zanidatamab in...

Merck agreed to acquire Cidara Therapeutics for $9.2 billion to add CD388, an investigational, long-acting, strain-agnostic antiviral designed to prevent symptomatic influenza in high-risk...